ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia
| Autor: | Sherene Loi, Adrienne Morey, Michael Bilous, Richard Bell, Andrew J. Spillane, Gelareh Farshid, Sunil R. Lakhani, Stephen B. Fox |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Receptor ErbB-2 Breast Neoplasms Expert committee Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Breast cancer Humans Medicine Pathology reporting In Situ Hybridization Societies Medical Clinical Oncology Australasia business.industry Australia medicine.disease Immunohistochemistry Pathologists Clinical Practice 030104 developmental biology 030220 oncology & carcinogenesis Family medicine In situ hybridisation Practice Guidelines as Topic Female business Asco cap |
| Zdroj: | Pathology. 51:345-348 |
| ISSN: | 0031-3025 |
| Popis: | The latest update to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing in breast cancer guidelines was published in 2018. A multidisciplinary expert committee, convened under the auspices of the Royal College of Pathologists of Australasia (RCPA) Structured Pathology Reporting framework, evaluated the implications of these guidelines for clinical practice in Australia. Following feedback from professional bodies, including the RCPA and CanSAC, peer review was invited. The final document prepared by the authors, endorsed by the Expert Committee RCPA Structured Pathology Reporting of Breast Cancer and by CanSAC, is published herein. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect